These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18341854)

  • 1. [My clinical experience with efalizumab in the Hospital of Conxo].
    Vázquez-Veiga HA; Seoane-Pose MJ; Fernández-Blanco MT
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():62-9. PubMed ID: 18341854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Is efalizumab a safe treatment for a chronic disease?].
    Daudén E; Oñate MJ
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():18-28. PubMed ID: 18341850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical experience with efalizumab in the Hospital of Cruces].
    Martínez de Lagrán Z; González Hermosa MR; Díaz-Pérez JL
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():74-81. PubMed ID: 18341856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Strategies to improve treatment with efalizumab].
    Carrascosa JM
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():37-50. PubMed ID: 18341852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Final recommendations to incorporate efalizumab into the clinical practice].
    García-Díez A; Ferrándiz C
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():82. PubMed ID: 18341857
    [No Abstract]   [Full Text] [Related]  

  • 6. [Which patient is a candidate for treatment with efalizumab and why?].
    Puig L
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():51-61. PubMed ID: 18341853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of excellent response to efalizumab. Experience in the University Hospital of Salamanca].
    Fernández López E; de Unamuno Pérez P
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():70-3. PubMed ID: 18341855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension.
    Talamonti M; Teoli M; Botti E; Spallone G; Chimenti S; Costanzo A
    Dermatology; 2011; 222(3):250-5. PubMed ID: 21494026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of short- and long-term efalizumab].
    Moreno Giménez JC; Galán Gutiérrez M; Jiménez Puya R
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():9-17. PubMed ID: 18341849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term control of psoriasis is necessary].
    Sánchez Carazo JL; Martínez Casimiro L; Alegre de Miguel V
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():29-36. PubMed ID: 18341851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical considerations of efalizumab therapy in patients with psoriasis.
    Hamilton TK
    Semin Cutan Med Surg; 2005 Mar; 24(1):19-27. PubMed ID: 15900795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group].
    Sánchez-Regaña M; Dilmé E; Puig L; Bordas X; Carrascosa JM; Ferran M; Herranz P; García-Bustinduy M; López Estebaranz JL; Alsina M; Rodríguez MA; Ribera M; Fernández-López E; Moreno JC; Belinchón Romero I; Vidal D;
    Actas Dermosifiliogr; 2010 Mar; 101(2):156-63. PubMed ID: 20223158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [PROLOGO: efalizumab].
    Vanaclocha Sebastián F
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():1. PubMed ID: 18341847
    [No Abstract]   [Full Text] [Related]  

  • 16. [The lymphocyte: protagonism in the new era of the biological therapies].
    Gutiérrez M; Ruiz Carrascosa JC
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():2-8. PubMed ID: 18341848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
    Alwawi EA; Krulig E; Gordon KB
    Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
    Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
    Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologicals in the treatment of psoriasis.
    Boker A; Kimball AB; Rolz-Cruz G
    Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
    Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
    Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.